How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

27 results for

Git Distributed Revision Control System

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Git Distributed Revision Control System

Git Distributed Revision Control System Git Distributed Revision Control System Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Git (...) Distributed Revision Control System Git Distributed Revision Control System Aka: Git Distributed Revision Control System From Related Chapters II. Precautions These git related notes are intended for the author of this website to have a quick reference for his own use Use these git related notes with caution (there are pitfalls, and there are likely better commands) III. Background: Windows Set-up Run git via powershell instead of Git-Bash Use Posh-Git package Use Powershell without the ISE (which

2018 FP Notebook

2. Git Distributed Revision Control System

Git Distributed Revision Control System Git Distributed Revision Control System Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Git (...) Distributed Revision Control System Git Distributed Revision Control System Aka: Git Distributed Revision Control System From Related Chapters II. Precautions These git related notes are intended for the author of this website to have a quick reference for his own use Use these git related notes with caution (there are pitfalls, and there are likely better commands) III. Background: Windows Set-up Run git via powershell instead of Git-Bash Use Posh-Git package Use Powershell without the ISE (which

2015 FP Notebook

3. ESC/ESH Management of Arterial Hypertension

day) ONTARGET Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial PAC Plasma aldosterone concentration PAD Peripheral artery disease PATHS Prevention and Treatment of Hypertension Study PRA Plasma renin activity PRC Plasma renin concentration PROGRESS Perindopril protection against recurrent stroke study PWV Pulse wave velocity RAS Renin–angiotensin system RCT Randomized controlled trial RWT Relative wall thickness SBP Systolic blood pressure SCOPE Study on Cognition (...) therapy3090 8.21 Perioperative management of hypertension3090 9 Managing concomitant cardiovascular disease risk3091 9.1 Statins and lipid-lowering drugs3091 9.2 Antiplatelet therapy and anticoagulant therapy3091 9.3. Glucose-lowering drugs and blood pressure3092 10 Patient follow-up3092 10.1 Follow-up of hypertensive patients3092 10.2 Follow-up of subjects with high–normal blood pressure and white-coat hypertension3092 10.3 Elevated blood pressure at control visits3093 10.4 Improvement in blood pressure

Full Text available with Trip Pro

2018 European Society of Cardiology

4. Erectile Dysfunction

Education and Research, Inc. The Practice Guidelines Committee of the AUA selected the Panel Co-Chairs who in turn appointed the additional panel members with specific expertise in this area. The AUA conducted a thorough peer review process. The draft guideline document was distributed to 35 peer reviewers. The Panel reviewed and discussed all submitted comments and revised the draft as needed. Once finalized, the guideline was submitted for approval to the Practice Guidelines Committee, the Science (...) should be counseled regarding post-operative expectations. (Clinical Principle) 20. Penile prosthetic surgery should not be performed in the presence of systemic, cutaneous, or urinary tract infection. (Clinical Principle) 21. For young men with ED and focal pelvic/penile arterial occlusion and without documented generalized vascular disease or veno-occlusive dysfunction, penile arterial reconstruction may be considered. (Conditional Recommendation; Evidence Level: Grade C) 22. For men with ED

2018 American Urological Association

5. Erectile Dysfunction

Guidelines Committee of the AUA selected the Panel Co-Chairs who in turn appointed the additional panel members with specific expertise in this area. The AUA conducted a thorough peer review process. The draft guideline document was distributed to 35 peer reviewers. The Panel reviewed and discussed all submitted comments and revised the draft as needed. Once finalized, the guideline was submitted for approval to the Practice Guidelines Committee, the Science and Quality Council, and subsequently (...) injection test should be performed. (Clinical Prin- ciple) 18. Men with ED should be informed regarding the treatment option of penile prosthesis implantation, including dis- cussion of benefits and risks/burdens. (Strong Recommendation; Evidence Level: Grade C) 19. Men with ED who have decided on penile implantation surgery should be counseled regarding post-operative expectations. (Clinical Principle) 20. Penile prosthetic surgery should not be performed in the presence of systemic, cutaneous

2018 American Urological Association

6. Point prevalence survey of healthcare-associated infections and antimicrobial use in European acute care hospitals ? protocol version 5.3

AM Antimicrobial/antimicrobial agent AMR Antimicrobial resistance ATC Anatomical Therapeutic Chemical classification system (WHO) AU Antimicrobial use BSI Bloodstream infection CDC Centres for Disease Control and Prevention (Atlanta, USA) CDI Clostridium difficile infections CFU Colony-forming units CVC Central vascular catheter DSN Dedicated surveillance network EARS-Net European Antimicrobial Resistance Surveillance Network (at ECDC) ECDC European Centre for Disease Prevention and Control EEA (...) catheter SPI Structure and process indicator SSI Surgical site infection TESSy The European Surveillance System (ECDC’s web-based data reporting system for the surveillance of communicable diseases) TRICE Training in Infection Control in Europe (ECDC-sponsored follow-up project to IPSE WP1) WHO World Health Organization TECHNICAL DOCUMENT PPS of HAIs and antimicrobial use in European acute care hospitals – protocol version 5.3 1 Background and changes to the protocol In July 2008, the coordination

2016 European Centre for Disease Prevention and Control - Technical Guidance

7. Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline from the American College of Physicians

Health System, Philadelphia, Pennsylvania; Massachusetts General Hospital, Boston, Massachusetts; and Oregon Health and Science University, Portland, Oregon. Michael J. Barry, MD From American College of Physicians and University of Pennsylvania Health System, Philadelphia, Pennsylvania; Massachusetts General Hospital, Boston, Massachusetts; and Oregon Health and Science University, Portland, Oregon. Linda L. Humphrey, MD, MPH From American College of Physicians and University of Pennsylvania Health (...) System, Philadelphia, Pennsylvania; Massachusetts General Hospital, Boston, Massachusetts; and Oregon Health and Science University, Portland, Oregon. Mary Ann Forciea, MD From American College of Physicians and University of Pennsylvania Health System, Philadelphia, Pennsylvania; Massachusetts General Hospital, Boston, Massachusetts; and Oregon Health and Science University, Portland, Oregon. for the Clinical Guidelines Committee of the American College of Physicians Author, Article, and Disclosure

Full Text available with Trip Pro

2017 American College of Physicians

8. Adult Non-Hodgkin Lymphoma Treatment (PDQ®): Health Professional Version

described pathologic subtypes have changed. As a result, the Working Formulation has become outdated and less useful to clinicians and pathologists. Thus, European and American pathologists have proposed a new classification, the Revised European American Lymphoma (REAL) classification.[ - ] Since 1995, members of the European and American Hematopathology societies have been collaborating on a new World Health Organization (WHO) classification, which represents an updated version of the REAL system (...) is similar to that of other low-grade lymphomas, especially diffuse, small lymphocytic lymphoma/chronic lymphocytic leukemia.[ , - ] If the viscosity relative to water is greater than four, the patient may have manifestations of hyperviscosity. Plasmapheresis is useful for temporary, acute symptoms (such as retinopathy, congestive heart failure, and central nervous system [CNS] dysfunction) but can be combined with chemotherapy for prolonged control of the disease. Symptomatic patients with a serum

2018 PDQ - NCI's Comprehensive Cancer Database

9. Reducing the Risk - Thrombosis and Embolism during Pregnancy and the Puerperium

, Labour and after Vaginal Delivery’ and revised in 2009 under the title ‘Reducing the Risk of Thrombosis and Embolism during Pregnancy and the Puerperium’. Executive summary of recommendations Prepregnancy and antenatal risk assessment What are the risk factors for venous thromboembolism (VTE) in pregnancy and the puerperium and what is the magnitude of risk for these factors? All women should undergo a documented assessment of risk factors for VTE in early pregnancy or prepregnancy. Risk assessment (...) identifiable risk factors 3,4 and a similar proportion (70%) from the UK Obstetric Surveillance System (UKOSS) cohort (n = 143) of fatal (3.5%) and nonfatal antenatal PE also had identifiable risk factors. 7 The UK incidence of antenatal PE calculated in the UKOSS study is 1.3 per 10 000 maternities. 7 Although the relative risk of VTE in pregnancy is increased four- to six-fold 8,9 and this is increased further postpartum, 9–11 the absolute risk is low with an overall incidence of VTE in pregnancy

2015 Royal College of Obstetricians and Gynaecologists

10. Rucaparib camsylate - Ovarian Neoplasms

. Management 11 2.2. Quality aspects 14 2.2.1. Introduction 14 2.2.2. Active Substance 14 General information 14 Manufacture, characterisation and process controls 15 Specification 16 Stability 16 2.2.3. Finished Medicinal Product 17 Description of the product and Pharmaceutical development 17 Manufacture of the product and process controls 18 Product specification 18 Stability of the product 18 Adventitious agents 19 2.2.4. Discussion on chemical, pharmaceutical and biological aspects 19 2.2.5 (...) for Pharmaceuticals for Human Use INN International Nonproprietary Name IPC in-process control IR infrared IRR independent radiological review IV intravenous KF Karl Fischer titration LDPE low density polyethylene LPI last patient in MAA Marketing Authorization Application MAH marketing authorization holder MATE multidrug and toxin extrusion transporter MHRA Medicines and Healthcare products Regulatory Agency MDR1 multidrug resistance protein 1 MDS myelodysplastic syndrome MedDRA Medical Dictionary for Regulatory

2018 European Medicines Agency - EPARs

11. South Australian gynaecological cancer pathway

with the aim to maximize quality of life. Recommendations Stage in Cancer Journey Pathway Recommendations System Recommendation All stages of the cancer journey Psychosocial support to be available for women at all stages of the cancer journey in public and private care. A suitable location to be provided for psychosocial counselling. Increased and ongoing education and training for all staff regarding the role of psychosocial support. Increased access to specialised psychosocial support services (...) should be commenced as teenagers. Gynaecological cancer education should be part of sexual education at school Best practise referral systems and timely access to screening. Ongoing information of GPs regarding available services and referral methods Women should have access to information about screening and cancer related risk factors. Information should be easily accessible from both websites and primary health care clinics. Page 7 of 58 Cervical screening should be offered by all primary

2014 Clinical Practice Guidelines Portal

12. Royal Flying Doctor Service Western Operations Clinical manual part 1.Clinical guidelines

of agents. Additional drugs or extra quantities of drugs may be carried for specific cases. Part 5 – Standard Aircraft Equipment List This section lists the minimum equipment on each aircraft, irrespective of the different storage options and configuration of different aircraft types. Updates The manual is distributed to all RFDS Flight Nurses and Medical Officers with additional reference copies kept at each Base. Printed copies are controlled documents. Electronic versions are also available (...) blood count CNS Central nervous system FFP Fresh frozen plasma CPAP Continuous positive airway pressure FHR Foetal heart rate RFDS Western Operations Version 6.0 Clinical Manual Issue Date: January 2013 Part 1 - Clinical Guidelines Abbreviations & Measures ii FM Foetal movements NGT nasogastric tube GCS Glasgow coma score NIBP Non-invasive blood pressure GIT Gastrointestinal tract NIV Non invasive ventilation GPS Global positioning system NM Neuromuscular GTN Glyceryl trinitrate NSAIDS Non-steroidal

2014 Clinical Practice Guidelines Portal

13. HIV, viral hepatitis and STIs - a guide for primary care

HEPATITIS AND STIS: A GUIDE FOR PRIMARY CARE ISBN 978-0-9579114-8-2 is published by the: Australasian Society for HIV Medicine (ASHM) Locked Bag 5057, Darlinghurst, NSW 1300 Telephone (61) (02) 8204 0700 Facsimile (61) (02) 9212 2382 Email ashm@ashm.org.au Website http://www.ashm.org.au First published 2001 Reprint (with revisions) 2004, 2008 2014 update and expansion to include HCV treatments, new chapters on HBV and biomedical prevention EXPERT REFERENCE GROUP (Editorial Committee): Michael Burke (...) Rigg (2008 Edition); Mary Sinclair (2008 Edition) Vanessa Towell, Emily Wheeler, Anna Roberts; Stephanie McLean; Mary Sinclair (2014 Edition) Indexing Jeanne Rudd (2014) Design & Layout Renee Bennett (2014 Edition); Shehana Mohammed (2008 Edition); McGill Design Group (2004 Edition) Additional input Special thanks to Dr David Baker (ASHM) for the revision and use of his HIV treatment tables in Chapter 10, Ms Tiia Harrison (AVIL) for updating the safer injecting content in appendix 4 and Associate

2014 Clinical Practice Guidelines Portal

14. Adult Non-Hodgkin Lymphoma Treatment (PDQ®): Health Professional Version

described pathologic subtypes have changed. As a result, the Working Formulation has become outdated and less useful to clinicians and pathologists. Thus, European and American pathologists have proposed a new classification, the Revised European American Lymphoma (REAL) classification.[ - ] Since 1995, members of the European and American Hematopathology societies have been collaborating on a new World Health Organization (WHO) classification, which represents an updated version of the REAL system (...) is similar to that of other low-grade lymphomas, especially diffuse, small lymphocytic lymphoma/chronic lymphocytic leukemia.[ , - ] If the viscosity relative to water is greater than four, the patient may have manifestations of hyperviscosity. Plasmapheresis is useful for temporary, acute symptoms (such as retinopathy, congestive heart failure, and central nervous system [CNS] dysfunction) but can be combined with chemotherapy for prolonged control of the disease. Symptomatic patients with a serum

2016 PDQ - NCI's Comprehensive Cancer Database

15. Screening, Monitoring, and Treatment of Stage 1-3 Chronic Kidney Disease: A Clinical Practice Guideline from the American College of Physicians

and for an American College of Physicians Clinical Practice Guideline. Ann Intern Med 2012 156 570-81 Barrett BJ , Garg AX , Goeree R , Levin A , Molzahn A , Rigatto C . et al A nurse-coordinated model of care versus usual care for stage 3/4 chronic kidney disease in the community: a randomized controlled trial. Clin J Am Soc Nephrol 2011 6 1241-7 United States Renal Data System. United States Renal Data System 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United (...) States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive Kidney Diseases; 2010. Accessed at on 10 October 2013. Centers for Disease Control and Prevention. Chronic Kidney Disease Surveillance System. Atlanta: U.S. Department of Health and Human Services. Accessed at on 8 October 2013. Ryan TP , Sloand JA , Winters PC , Corsetti JP , Fisher SG . Chronic kidney disease prevalence and rate of diagnosis. Am J Med 2007 120 981-6 Levey AS , Coresh J , Greene T

2013 American College of Physicians

16. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease

, ACCF Interventional Scientific Council, and the AHA Council on Clinical Cardiology. Reviewers' RWI information was collected and distributed to the writing committee and is published in this document (Appendix 2). Because extensive peer review comments resulted in substantial revision, the guideline was subjected to a second peer review by all official and organizational reviewers. Lastly, the imaging sections were peer reviewed separately, after an update to that evidence base. This document (...) , and revising practice guidelines for cardiovascular diseases and procedures, directs and oversees this effort. Writing committees are charged with regularly reviewing and evaluating all available evidence to develop balanced, patient-centric recommendations for clinical practice. Experts in the subject under consideration are selected by the ACCF and AHA to examine subject-specific data and write guidelines in partnership with representatives from other medical organizations and specialty groups. Writing

2011 American Heart Association

17. Otezla - apremilast

16 prior to database lock and unblinding. The Applicant decided to do this because, given the design of the study, Week 16 provided the only true placebo-controlled evaluation of the efficacy of APR, due to the early escape provision at this time-point for placebo-treated patients. The fact that recent clinical trials evaluating other systemic therapies in PsA have used primary endpoints between Weeks 12 to 16 supports the validity of this change (Antoni, 2005; Mease, 2005b; Kavanaugh, 2009). EMA (...) in acetone, acetonitrile, methylethylketone, methylene chloride and tetrahydrofuran. Active substance is classified as having low solubility and low permeability according to Biopharmaceutical Classification System (i.e. BCS Class 4). The chemical structure of apremilast has been adequately demonstrated by elemental analysis, IR and UV spectroscopy, 1 H and 13 C NMR spectroscopy, mass spectrometry, single crystal X-ray diffraction and XRPD, DSC, TGA, DVS and particle size distribution, and a polymorphism

2015 European Medicines Agency - EPARs

18. Fexeric - ferric citrate coordination complex

erythrocyte PCS Potentially clinically significant PD parenteral dialysis PDE Permitted daily exposure Ph. Eur. European Pharmacopoeia PT prothrombin time PTH parathyroid hormone QTc corrected qt interval RBC red blood cell count RDW red cell distribution width RES reticuloendothelial system RH relative humidity s.c. Subcutaneous SmPC Summary of product characteristics SP (SAP) Safety assessment period (safety analysis population) Tbili total bilirubin TG Triglycerides TIBC total iron binding capacity t (...) iron assay (titrimetric), citrate content (HPLC), iron impurities (XRPD), ferrous iron content (titrimetric), chloride content (titrimetric), citrate impurities (HPLC), residual solvents (GC), water content (KF), acid insolubles Assessment report EMA/CHMP/535898/2015 Page 13/86 (gravimetric), trace metal impurities (ICP-MS and ICP-OES), particle size distribution (Ph. Eur.), Brunauer–Emmett–Teller (BET) specific surface area (Ph. Eur.) and microbial limits (Ph. Eur.). Impurities are controlled

2015 European Medicines Agency - EPARs

19. Anoro (umeclidinium bromide / vilanterol trifenatate)

Benefits 302 Risks 303 Assessment report EMA/CHMP/163509/2014 Page 3/308 Benefit-risk balance 304 Discussion on the benefit-risk balance 305 4. Recommendations 306 Assessment report EMA/CHMP/163509/2014 Page 4/308 List of abbreviations AC Active controlled ADME Absorption, distribution, metabolism and elimination AE Adverse Event AESI Adverse event of special interest APSD Aerodynamic particle size distribution AUC (0-24) Area under the concentration-time curve over the once-daily dosing interval AUC (...) to systemic exposure following inhalation administration. Oral absorption of GW642444 in human, as in animals, was good with at least 50% orally absorbed based on urinary recovery of DRM following administration of 14C-GW642444 in solution (study B2C106181). Exposure to GW642444 represented a very small percentage (in the region of human liver blood flow). The steady state volume of distribution of GW642444 was high in the rat and human but moderate in the dog, exceeding total body water in all species

2014 European Medicines Agency - EPARs

20. Laventair - umeclidinium bromide / vilanterol

Benefits 303 Risks 304 Assessment report EMA/CHMP/163509/2014 Page 3/309 Benefit-risk balance 305 Discussion on the benefit-risk balance 306 4. Recommendations 307 Assessment report EMA/CHMP/163509/2014 Page 4/309 List of abbreviations AC Active controlled ADME Absorption, distribution, metabolism and elimination AE Adverse Event AESI Adverse event of special interest APSD Aerodynamic particle size distribution AUC (0-24) Area under the concentration-time curve over the once-daily dosing interval AUC (...) ). The steady state volume of distribution of GW642444 was high in the rat and human but moderate in the dog, exceeding total body water in all species. In repeat dose inhalation studies using dry powder formulations, systemic exposure to GW642444 (AUC0-t and Cmax) increased with increasing dose in a proportional or less than dose-proportional manner; subproportionality was generally associated with higher doses. There was little evidence of accumulation of GW642444 exposure with time, although increased

2014 European Medicines Agency - EPARs

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>